


Regeneron Pharmaceuticals, Inc. (REGN)

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0000872589

[illegible]

Letter at every rescans

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only



Business, in the company's words

opening of Item 1 of the 10-K received Feb 4, 2026

This Annual Report on Form 10-K contains forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. (where applicable, together with its subsidiaries, "Regeneron," "Company," "we," "us," and "our"), and actual events or results may differ materially from these forward-looking statements. Words such as "anticipate," "expect," "intend," "plan," "believe," "seek," "estimate," variations of such words, and similar expressions are

intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words.


The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 78.5						
Gross profitability		not computable	32.2%			one or more required annual facts are missing
Return on invested capital		not computable	9.3%			one or more required annual facts are missing
Accruals ratio		(1.2%)	(6.6%)	78.5	811	2025-12-31
Gross margin stability, five years		not computable	2.8 pts			five annual gross margins are required; found 0
Solvency, sleeve percentile 27.1						
Twelve-month failure probability		not computable	0.07%			liabilities and a nearby cover-page share count are required at 2026-06-30
Altman Z double-prime		9.21	(0.31)	9.9	756	2025-12-31
Net debt to EBITDA		not computable	1.82x			one or more required annual facts are missing
Interest coverage		not computable	(4.51x)			latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31
Current ratio		4.13x	2.96x	44.3	839	2025-12-31
Growth and financing, sleeve percentile 61.7						
Revenue growth, three-year compound		5.6%	10.0%	57.5	415	2025-12-31
Free cash flow growth, three-year compound		(2.7%)	10.9%	77.9	96	2025-12-31
Reinvestment rate		(23.0%)	37.1%	81.6	104	2025-12-31
Asset growth, three years		11.6%	2.1%	30.0	704	2025-12-31
Net share issuance, one year		not computable	2.5%			raw and split-adjusted prices do not align at 2012-02-10

Among 371 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
259	Scienture Holdings, Inc. (SCNX)	69.7	D	fortress balance sheet
260	Rockwell Medical, Inc. (RMTI)	70.0	D	
261	Bioventus Inc. (BVS)	70.3	D	
262	Ovid Therapeutics Inc. (OVID)	70.5	D	dilution, short runway
263	uniQure N.V. (QURE)	70.8	D	fortress balance sheet
264	Regeneron Pharmaceuticals, Inc. (REGN) <	71.1	D	
265	AbCellera Biologics Inc. (ABCL)	71.4	D	
266	Cumberland Pharmaceuticals Inc. (CPIX)	71.6	D	
267	Bausch & Lomb Corp. (BLCO)	71.9	D	
268	Pennant Group, Inc. (PNTG)	72.2	D	
269	Bausch Health Companies Inc. (BHC)	72.4	D	

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	42.8%	8.0%	72
Distance from 52-week high	(13.2%)	(31.4%)	76
EBIT to enterprise value	not computable	(1.5%)	
Free cash flow yield	not computable	(1.0%)	
Book value to price	not computable	0.28	
Sales to price	not computable	0.31	
Composite equity issuance, five years	not computable	20.3%	
Relative strength against the sector, log excess return	0.14	(0.14)	72

Diagnostics

not in the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	pass
Operating cash flow above zero	pass
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	pass
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	\$2.5B
Operating cash flow, four quarters	\$4.7B
Months of runway	not finite

Days since last periodic filing

71 (10-Q received Jul 30, 2026)

Median daily dollar volume, 63 sessions

\$496.3M

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	net income	us-gaap:NetIncomeLoss	\$4.5B	2025-12-31	2026-02-04	10-K	0000872589-26-000008
2	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$5.0B	2025-12-31	2026-02-04	10-K	0000872589-26-000008
3	assets	us-gaap:Assets	\$40.6B	2025-12-31	2026-02-04	10-K	0000872589-26-000008
4	assets	us-gaap:Assets	\$37.8B	2024-12-31	2026-02-04	10-K	0000872589-26-000008
5	current assets	us-gaap:AssetsCurrent	\$18.0B	2025-12-31	2026-02-04	10-K	0000872589-26-000008
6	current liabilities	us-gaap:LiabilitiesCurrent	\$4.4B	2025-12-31	2026-02-04	10-K	0000872589-26-000008
7	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	\$35.8B	2025-12-31	2026-02-04	10-K	0000872589-26-000008
8	operating income	us-gaap:OperatingIncomeLoss	\$3.6B	2025-12-31	2026-02-04	10-K	0000872589-26-000008
9	book equity	us-gaap:StockholdersEquity	\$31.3B	2025-12-31	2026-02-04	10-K	0000872589-26-000008
10	liabilities	us-gaap:Liabilities	\$9.3B	2025-12-31	2026-02-04	10-K	0000872589-26-000008
11	operating income	us-gaap:OperatingIncomeLoss	\$4.0B	2023-12-31	2026-02-04	10-K	0000872589-26-000008
12	interest expense	us-gaap:InterestExpense	\$73.0M	2023-12-31	2024-02-05	10-K	0001804220-24-000009
13	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$14.3B	2025-12-31	2026-02-04	10-K	0000872589-26-000008
14	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$14.2B	2024-12-31	2026-02-04	10-K	0000872589-26-000008
15	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$13.1B	2023-12-31	2026-02-04	10-K	0000872589-26-000008
16	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$12.2B	2022-12-31	2025-02-05	10-K	0001804220-25-000011
17	capital expenditure	us-gaap:PaymentsToAcquireProductiveAssets	\$898.4M	2025-12-31	2026-02-04	10-K	0000872589-26-000008
18	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$4.4B	2024-12-31	2026-02-04	10-K	0000872589-26-000008
19	capital expenditure	us-gaap:PaymentsToAcquireProductiveAssets	\$755.9M	2024-12-31	2026-02-04	10-K	0000872589-26-000008
20	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$4.6B	2023-12-31	2026-02-04	10-K	0000872589-26-000008
21	capital expenditure	us-gaap:PaymentsToAcquireProductiveAssets	\$718.6M	2023-12-31	2026-02-04	10-K	0000872589-26-000008
22	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$5.0B	2022-12-31	2025-02-05	10-K	0001804220-25-000011
23	capital expenditure	us-gaap:PaymentsToAcquireProductiveAssets	\$590.1M	2022-12-31	2025-02-05	10-K	0001804220-25-000011
24	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	\$543.7M	2025-12-31	2026-02-04	10-K	0000872589-26-000008
25	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraord	\$5.2B	2025-12-31	2026-02-04	10-K	0000872589-26-000008
26	income tax	us-gaap:IncomeTaxExpenseBenefit	\$725.8M	2025-12-31	2026-02-04	10-K	0000872589-26-000008
27	current assets	us-gaap:AssetsCurrent	\$18.7B	2024-12-31	2026-02-04	10-K	0000872589-26-000008
28	current liabilities	us-gaap:LiabilitiesCurrent	\$3.9B	2024-12-31	2026-02-04	10-K	0000872589-26-000008
29	assets	us-gaap:Assets	\$33.1B	2023-12-31	2025-02-05	10-K	0001804220-25-000011
30	assets	us-gaap:Assets	\$29.2B	2022-12-31	2024-02-05	10-K	0001804220-24-000009
31	shares outstanding	dei:EntityCommonStockSharesOutstanding	91,779,465	2012-02-10	2012-02-21	10-K	0001206774-12-000709
32	shares outstanding	dei:EntityCommonStockSharesOutstanding	87,777,008	2011-02-11	2011-02-17	10-K	0001206774-11-000263